Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02432066
Other study ID # IRB201500393
Secondary ID Nixon2015R21DA03
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 29, 2018
Est. completion date December 29, 2020

Study information

Verified date March 2019
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Attempts to quit cigarette smoking are often accompanied by negative mood and problems in attention and memory. These effects, in turn, may contribute to smoking relapse. This exploratory/developmental project examines the effects of a novel medication, GTS-21, on individuals interested in smoking cessation. It is hypothesized that GTS-21 will reduce negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and women who are chronic cigarette smokers.


Description:

The project is a clinical trial assessing the effects of GTS-21 (an α7 nicotinic receptor partial agonist) on smoking, mood, neurocognition, and neurophysiology, in a small sample of chronic smokers who are currently healthy and interested in smoking cessation. Using a double-blind, placebo controlled, parallel group design, 54 (27 women) community smokers who have demonstrated a readiness to quit will participate over a 7 week active trial. Subjects will be randomly assigned to active drug or placebo groups. Across the study period, participants will undergo repeated neurobehavioral testing, laboratory assessments of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood state and side-effects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 29, 2020
Est. primary completion date December 29, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

- Minimum of 12 years of education

- Must report typical daily smoking of > 10 cigarettes/day over the previous year

- Must report a history of at least 3 years of regular smoking

- Must provide carbon monoxide measures of at least 6.5 ppm

- Must report a willingness to quit smoking

Exclusion Criteria:

- Participants engaged in behavioral and/or nicotine replacement therapies, or assisted quit efforts, within previous 6 months.

- Must not meet criteria for other substance dependence or major psychiatric disorders.

- Must be absent chronic medical conditions that might jeopardize health and safety, confound data interpretation or that contraindicate the administration of compounds acting at nAChR sites. This list includes disorders with direct effects on neurologic function (e.g., seizure disorders, transient ischemic events, chronic or active hepatic disease), metabolic disorders (e.g., uncontrolled Type 2 diabetes), or cardiovascular disease (e.g., hypertension, mitral valve compromise, tachycardia, or irregular heart rates).

- Must not smoke only cigars, pipes or hookahs or use nicotine products but not cigarettes

- Must not report current use of nicotine replacement therapies (i.e., occasions of > 4 h/week during a typical week, even if not used as a cessation aid)

- Must not have used bupropion within the previous year

- Must not report any past use (regardless of year) of varenicline

- Women may not be breastfeeding, pregnant or intending to become pregnant during the study period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GTS-21
GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
Placebo
Oral placebo pills, compounded by the UF investigational pharmacy

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Florida National Institute on Drug Abuse (NIDA)

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Reported Nicotine Use from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8 Nicotine use will be assessed using Timeline Followback procedures. Nicotine use will be reported to a trained interviewer using a Timeline Followback calendar, facilitated by calendars distributed to participants. Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
Primary Change in Carbon Monoxide (CO) from baseline at weeks 5, 8 Expired Carbon Monoxide levels will be quantified in parts per million. Change in baseline at Week 5, Week 8
Primary Change in Urine Cotinine (COT) from baseline at weeks 5, 8 Cotinine excreted in urine will be quantified in ng/mL Change in baseline at Week 5, Week 8
Secondary Change in Beck Depression Inventory - II (BDI-II) from baseline at weeks 5, 8 The Beck Depression Inventory will be used to quantify depressive symptomatology. The measure is a 21-item, self-report, multiple-choice inventory, with scores ranging from 0-63. Change in baseline at Week 5, Week 8
Secondary Change in State Anxiety Inventory (AI) from baseline at weeks 5, 8 The State Anxiety Inventory will be used to quantify anxiety symptomatology. The measure is a 20-item, self-report, multiple-choice inventory, with scores ranging from 20-80. Change in baseline at Week 5, Week 8
Secondary Change in State Anger (ANG-S) from baseline at weeks 5, 8 The Spielberger State Anger Inventory will be used to assess state anger. The measure is a 20-item, self-report, multiple-choice inventory, with scores ranging from 20-80. Change in baseline at Week 5, Week 8
Secondary Pill Count - Week 1 Medication compliance will be assessed with pill counts. Week 1
Secondary Pill Count - Week 5 Medication compliance will be assessed with pill counts. Week 5
Secondary Pill Count - Week 8 Medication compliance will be assessed with pill counts. Week 8
Secondary Change in Minnesota Withdrawal Scale from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8 The Minnesota Withdrawal Scale measures self-reported severity of nicotine withdrawal. The measure has 15 items, with five possible responses (0-5), thus scores on the scale range from 0 to 60. Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 1 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 1
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 2 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 2
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 3 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 3
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 4 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 4
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 5 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 5
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 6 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 6
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 7 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 7
Secondary Systematic Assessment for Treatment Emergent Events (SAFTEE) - Week 8 The SAFTEE assesses potential side effects across a broad range of potential somatic effects. The measure includes 132 potential areas in which participants might report effects, including opportunities for the participant to describe otherwise unlisted option. Each area is scored on a 5-point scale. Week 8
Secondary Change in Profile of Mood States 2-A from Baseline at Week 1, 2, 3, 4, 5, 6, 7, 8 The Profile of Mood States-2 (short-form for adults) The POMS 2 is a multi-dimensional, assessment of transient moods, and states of affect. The measure includes 35 items, each rated on a 5-point scale (0-4). Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
Secondary Rapid Visual Information Processing task (Behavior) - Baseline The Rapid Visual Information Processing task is an attention task. Subjects are instructed to detect and respond as quickly, yet as accurately, as possible when a target of three consecutive odd or even digits are presented. Digits are presented at the rate of approximately 100 per minute. Hits are separated by a varying number of stimuli (e.g., between 5 and 30 digits). Dependent variables will include accuracy and reaction time. Baseline
Secondary Rapid Visual Information Processing task - (Behavior) - Week 8 The Rapid Visual Information Processing task is an attention task. Subjects are instructed to detect and respond as quickly, yet as accurately, as possible when a target of three consecutive odd or even digits are presented. Digits are presented at the rate of approximately 100 per minute. Hits are separated by a varying number of stimuli (e.g., between 5 and 30 digits). Dependent variables will include accuracy and reaction time. Week 8
Secondary Rapid Visual Information Processing task - (EEG) - Baseline The Rapid Visual Information Processing task is an attention task. Subjects are instructed to detect and respond as quickly, yet as accurately, as possible when a target of three consecutive odd or even digits are presented. Digits are presented at the rate of approximately 100 per minute. Hits are separated by a varying number of stimuli (e.g., between 5 and 30 digits). Dependent variables will include electrophysiological measures gathered during task participation, including the peak and latency of the P3, P2, and N1 components. Baseline
Secondary Rapid Visual Information Processing task - (EEG) - Week 8 The Rapid Visual Information Processing task is an attention task. Subjects are instructed to detect and respond as quickly, yet as accurately, as possible when a target of three consecutive odd or even digits are presented. Digits are presented at the rate of approximately 100 per minute. Hits are separated by a varying number of stimuli (e.g., between 5 and 30 digits). Dependent variables will include electrophysiological measures gathered during task participation, including the peak and latency of the P3, P2, and N1 components. Week 8
Secondary Measurement of GTS-21 Concentration in Blood - Week 5 Blood samples will be collected and analyzed for their concentration of GTS-21. Week 5
Secondary Measurement of GTS-21 Concentration in Blood - Week 8 Blood samples will be collected and analyzed for their concentration of GTS-21. Week 8
Secondary Trail Making Test A (TMT-A) - Baseline The Trail Making Test A consists of numbered 25 circles distributed over a sheet of paper. Participants draw a line between consecutive circles as quickly and accurately as possible. The dependent variable is time to completion of the task. Baseline
Secondary Trail Making Test A (TMT-A) - Week 5 The Trail Making Test A consists of numbered 25 circles distributed over a sheet of paper. Participants draw a line between consecutive circles as quickly and accurately as possible. The dependent variable is time to completion of the task. Week 5
Secondary Trail Making Test A (TMT-A) - Week 8 The Trail Making Test A consists of numbered 25 circles distributed over a sheet of paper. Participants draw a line between consecutive circles as quickly and accurately as possible. The dependent variable is time to completion of the task. Week 8
Secondary Trail Making Test B (TMT-B) - Baseline The Trail Making Test B consists of 25 circles distributed over a sheet of paper, labeled with numbers (1-13) and letters (A-L). Participants draw a line between circles, alternating between consecutive numbers and letters (i.e., 1 to A, A to 2, 2 to B, etc.) as quickly and accurately as possible. The dependent variable is time to completion of the task. Baseline
Secondary Trail Making Test B (TMT-B) - Week 5 The Trail Making Test B consists of 25 circles distributed over a sheet of paper, labeled with numbers (1-13) and letters (A-L). Participants draw a line between circles, alternating between consecutive numbers and letters (i.e., 1 to A, A to 2, 2 to B, etc.) as quickly and accurately as possible. The dependent variable is time to completion of the task. Week 5
Secondary Trail Making Test B (TMT-B) - Week 8 The Trail Making Test B consists of 25 circles distributed over a sheet of paper, labeled with numbers (1-13) and letters (A-L). Participants draw a line between circles, alternating between consecutive numbers and letters (i.e., 1 to A, A to 2, 2 to B, etc.) as quickly and accurately as possible. The dependent variable is time to completion of the task. Week 8
Secondary N-Back Working Memory Task (Behavior) - Baseline The 'n-back' test is a measure of working memory entailing the presentation of a stream of numbers, presented singly, and separated by neutral stimuli (i.e., "+"). Ss press a button when the presented stimulus is the same as the one that occurred 'n-back', i.e., some specific number back. The 'n-back' will vary across blocks (i.e., 1 or 2 back). A control condition, requiring Ss to press the button when a blank slide appears, will also be employed. Dependent variables will include accuracy and reaction time. Baseline
Secondary N-Back Working Memory Task (Behavior) - Week 8 The 'n-back' test is a measure of working memory entailing the presentation of a stream of numbers, presented singly, and separated by neutral stimuli (i.e., "+"). Ss press a button when the presented stimulus is the same as the one that occurred 'n-back', i.e., some specific number back. The 'n-back' will vary across blocks (i.e., 1 or 2 back). A control condition, requiring Ss to press the button when a blank slide appears, will also be employed. Dependent variables will include accuracy and reaction time. Week 8
Secondary N-Back Working Memory Task (EEG) - Baseline The 'n-back' test is a measure of working memory entailing the presentation of a stream of numbers, presented singly, and separated by neutral stimuli (i.e., "+"). Ss press a button when the presented stimulus is the same as the one that occurred 'n-back', i.e., some specific number back. The 'n-back' will vary across blocks (i.e., 1 or 2 back). A control condition, requiring Ss to press the button when a blank slide appears, will also be employed. Dependent variables will include electrophysiological measures gathered during task participation, including the peak and latency of the P3, P2, and N1 components. Baseline
Secondary N-Back Working Memory Task (EEG) - Week 8 The 'n-back' test is a measure of working memory entailing the presentation of a stream of numbers, presented singly, and separated by neutral stimuli (i.e., "+"). Ss press a button when the presented stimulus is the same as the one that occurred 'n-back', i.e., some specific number back. The 'n-back' will vary across blocks (i.e., 1 or 2 back). A control condition, requiring Ss to press the button when a blank slide appears, will also be employed. Dependent variables will include electrophysiological measures gathered during task participation, including the peak and latency of the P3, P2, and N1 components. Week 8
Secondary Simple Reaction Time Test - Baseline In this computerized task, subjects must press a button as quickly as possible each time a designed symbol appears on the screen. This test serves as a perceptual-motor control. The dependent measure is reaction time. Baseline
Secondary Simple Reaction Time Test - Week 5 In this computerized task, subjects must press a button as quickly as possible each time a designed symbol appears on the screen. This test serves as a perceptual-motor control. The dependent measure is reaction time. Week 5
Secondary Simple Reaction Time Test - Week 8 In this computerized task, subjects must press a button as quickly as possible each time a designed symbol appears on the screen. This test serves as a perceptual-motor control. The dependent measure is reaction time. Week 8
Secondary Little Man Test - Baseline In this computerized mental rotation test, subjects must indicate the hand in which a simulated figure holds an object. The dependent measures are accuracy and reaction time. Baseline
Secondary Little Man Test - Week 8 In this computerized mental rotation test, subjects must indicate the hand in which a simulated figure holds an object. The dependent measures are accuracy and reaction time. Week 8
Secondary Visual-Perceptual Analysis Test - Baseline In this computerized task, subjects must distinguish which of three similar shapes differs from the other two. Dependent measures include accuracy and reaction time. Baseline
Secondary Visual-Perceptual Analysis Test - Week 5 In this computerized task, subjects must distinguish which of three similar shapes differs from the other two. Dependent measures include accuracy and reaction time. Week 5
Secondary Visual-Perceptual Analysis Test - Week 8 In this computerized task, subjects must distinguish which of three similar shapes differs from the other two. Dependent measures include accuracy and reaction time. Week 8
Secondary Wisconsin Card Sorting Test - Baseline The Wisconsin Card Sort Test is a computerized task which requires subjects to match "cards" based on shifting matching rules which include color, shape, and number of symbols. The dependent measures for this task include accuracy and response time. Baseline
Secondary Wisconsin Card Sorting Test - Week 8 The Wisconsin Card Sort Test is a computerized task which requires subjects to match "cards" based on shifting matching rules which include color, shape, and number of symbols. The dependent measures for this task include accuracy and response time. Week 8
Secondary Sternberg Short-Term Memory Test - Baseline The Sternberg Short-Term Memory Test is a computerized task in which participants are shown four digits, presented one at a time, followed by a probe digit. They must determine if the probe digit was in the original set of digits, and recall the digits. The dependent variables are probe accuracy, number of correct recalls, and time to completion. Baseline
Secondary Sternberg Short-Term Memory Test - Week 8 The Sternberg Short-Term Memory Test is a computerized task in which participants are shown four digits, presented one at a time, followed by a probe digit. They must determine if the probe digit was in the original set of digits, and recall the digits. The dependent variables are probe accuracy, number of correct recalls, and time to completion. Week 8
Secondary Stroop Color Word Task - Baseline The Stroop Task is a measure of inhibitory control. Subjects are directed to name the colors words are printed in (i.e., "blue"), while ignoring the incongruent meaning of the words. The dependent measures include number correct and number completed. Baseline
Secondary Stroop Color Word Task - Week 8 The Stroop Task is a measure of inhibitory control. Subjects are directed to name the colors words are printed in (i.e., "blue"), while ignoring the incongruent meaning of the words. The dependent measures include number correct and number completed. Week 8
Secondary Digit Symbol Substitution Task - Baseline The Digit Symbol Substitution Task requires attention and set-switching. Subjects must translate between numbers and symbols, using a key provided. The dependent measure is number of correct responses completed. Baseline
Secondary Digit Symbol Substitution Task - Week 5 The Digit Symbol Substitution Task requires attention and set-switching. Subjects must translate between numbers and symbols, using a key provided. The dependent measure is number of correct responses completed. Week 5
Secondary Digit Symbol Substitution Task - Week 8 The Digit Symbol Substitution Task requires attention and set-switching. Subjects must translate between numbers and symbols, using a key provided. The dependent measure is number of correct responses completed. Week 8
Secondary Metabolic Panel - Baseline Liver Function Test will measure a standard array of blood chemistries, including electrolytes, blood glucose, protein, liver enzymes (aminotransferase/alanine aminotransferase), bilirubin, creatinine, and blood urea nitrogen. Baseline
Secondary Metabolic Panel - Week 2 Liver Function Test will measure a standard array of blood chemistries, including electrolytes, blood glucose, protein, liver enzymes (aminotransferase/alanine aminotransferase), bilirubin, creatinine, and blood urea nitrogen. Week 2
Secondary Metabolic Panel - Week 5 Liver Function Test will measure a standard array of blood chemistries, including electrolytes, blood glucose, protein, liver enzymes (aminotransferase/alanine aminotransferase), bilirubin, creatinine, and blood urea nitrogen. Week 5
Secondary Metabolic Panel - Week 8 Liver Function Test will measure a standard array of blood chemistries, including electrolytes, blood glucose, protein, liver enzymes (aminotransferase/alanine aminotransferase), bilirubin, creatinine, and blood urea nitrogen. Week 8
Secondary Metabolic Panel - Week 9 (Followup) Liver Function Test will measure a standard array of blood chemistries, including electrolytes, blood glucose, protein, liver enzymes (aminotransferase/alanine aminotransferase), bilirubin, creatinine, and blood urea nitrogen. Week 9
Secondary Urinalysis - Baseline Standard urinalysis will be conducted, including urine pH, red cell count, white cell count, specific gravity, and bacteria content. Baseline
Secondary Urinalysis - Week 2 Standard urinalysis will be conducted, including urine pH, red cell count, white cell count, specific gravity, and bacteria content. Week 2
Secondary Urinalysis - Week 5 Standard urinalysis will be conducted, including urine pH, red cell count, white cell count, specific gravity, and bacteria content. Week 5
Secondary Urinalysis - Week 8 Standard urinalysis will be conducted, including urine pH, red cell count, white cell count, specific gravity, and bacteria content. Week 8
Secondary Urinalysis - Week 9 (Followup) Standard urinalysis will be conducted, including urine pH, red cell count, white cell count, specific gravity, and bacteria content. Week 9
Secondary Electrocardiogram - Baseline Standard electrocardiographic data will be collected, including heart rate (BPM) and time between start of the Q wave and end of the T wave (QT interval). Baseline
Secondary Electrocardiogram - Week 1 Standard electrocardiographic data will be collected, including heart rate (BPM) and time between start of the Q wave and end of the T wave (QT interval). Week 1
Secondary Change in Reported Drug and Alcohol Use from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8 Drug and alcohol use will be assessed using Timeline Followback procedures. Drug and alcohol use will be reported to a trained interviewer using a Timeline Followback calendar, facilitated by calendars distributed to participants. Change in baseline at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8
Secondary Change in Blood Pressure from baseline at weeks 2, 5, 8, 9 Systolic and Diastolic pressures will be collected. Change in baseline at Week 2, Week 5, Week 8, Week 9
See also
  Status Clinical Trial Phase
Completed NCT03960138 - Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Completed NCT04646668 - Comparative Abuse Liability Among African American and White Smokers N/A
Completed NCT02560324 - Effect of Ramelteon on Smoking Abstinence Phase 2
Completed NCT02347605 - Medicinal Nicotine for Preventing Cue Induced Craving N/A
Completed NCT01625767 - Tobacco Approach Avoidance Training for Adolescent Smokers-1 Phase 2
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Terminated NCT01800500 - Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers N/A
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT01337817 - A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers Phase 1
Completed NCT00967005 - N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Phase 2
Active, not recruiting NCT00751660 - Screening Methods in Finding Lung Cancer Early in Current or Former Smokers N/A
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00664261 - Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking N/A
Completed NCT00218179 - Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1 N/A
Completed NCT00158145 - Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2 Phase 2
Completed NCT01213524 - Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia Phase 2
Completed NCT00134927 - A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches N/A